Study Identifies Metabolic Vulnerability in Common Colorectal Cancer Type
A new study suggests that cancer cells with a specific, common genetic mutation may rely on a particular metabolic enzyme for survival, offering a potential new therapeutic strategy.
The research, published in a scientific journal, focuses on cancers with mutations in the APC gene, a frequent driver of colorectal cancer that has proven difficult to target directly with drugs.
The findings indicate that targeting a downstream metabolic requirement—the enzyme ALDH2—could be a viable strategy for treating cancers with APC mutations.
How the Discovery Was Made
Researchers used a combination of computational screening and laboratory experiments to identify this vulnerability. They found that cancer cells lacking functional APC protein appear to depend on the metabolic enzyme ALDH2 for survival.
When ALDH2 was inhibited, either genetically or pharmacologically, the effects were pronounced in APC-deficient models:
- Reduced cell proliferation
- Increased cell death
Notably, cells with intact, functional APC showed reduced sensitivity to ALDH2 inhibition, suggesting a potential therapeutic window.
Understanding the Mechanism
The study detailed the biological chain of events triggered by ALDH2 inhibition in these cancer cells:
- Inhibition leads to a buildup of reactive oxygen species (ROS), disrupting the cell's internal balance.
- This cellular stress activates specific stress-response pathways, including the ASK1/JNK signaling cascade.
- The activation of these pathways alters key regulators of apoptosis (programmed cell death), leading to an increase in pro-death proteins like BAX and a decrease in survival proteins like Bcl2.
- This imbalance ultimately drives the cancer cells to self-destruct.
Pharmacological inhibitors of ALDH2, including the compound disulfiram, were able to reproduce these anti-cancer effects in the laboratory models.
Research Implications and Next Steps
This discovery contributes to the growing field of research focused on finding and exploiting metabolic weaknesses in cancer cells. ALDH2 represents a potentially more accessible drug target compared to the genetic drivers of cancer, like mutated APC, which have been elusive.
The findings suggest that targeting downstream metabolic requirements, rather than the genetic mutation itself, could be a promising approach.
However, the authors note that further investigation is required to determine clinical applications. A key limitation of the study is that the research was conducted in laboratory models, and clinical translation to human patients has not yet been demonstrated.